More than 130 Natural Products Association members descended on Capitol Hill on May 12 for the trade group’s 2026 Fly-In Day, marking 90 years of NPA advocacy. The delegation pressed lawmakers to reject S. 3677 and H.R. 8370, modernize the drug preclusion clause, expand HSA and FSA access for supplements, and clarify FDA’s authority over a widening patchwork of state-level supplement rules.

The House version of the Dietary Supplement Listing Act, H.R. 8370, would require manufacturers, packers and distributors to file product names, ingredient lists, allergen statements, structure/function claims and electronic label copies with FDA for a public database. CRN backs the framework as a long-overdue transparency upgrade; NPA argues it duplicates existing cGMP requirements, raises compliance costs and offers little leverage against truly bad actors operating outside the legitimate supply chain.

Following FDA’s March 27 public meeting on dietary supplement innovation and the comment period that closed April 27, industry stakeholders are urging the agency to issue clear guardrails on how proteins, enzymes, microbials and precision-fermentation-derived ingredients fit within the DSHEA definition of a dietary ingredient. NDI safety and identity guidance remains on the agency’s 2026 priority deliverables list.

Israeli gummy specialist TopGum Industries completed its acquisition of PLD Manufacturing, valued at up to $35 million, securing its first U.S.-based manufacturing footprint with a New York facility built to FDA pharmaceutical standards. The companies also struck a parallel supply agreement to produce store-brand gummy lines, a category whose surging share of supplement sales has reshaped capacity planning across Israel, Canada and the U.S.

Seven years into commercial production, Nourished has shipped more than 60 million 3D-printed personalized gummy stacks and reached over 35,000 retail doors. The company’s internal data shows cognitive function and neuroprotection have leapt to the top of consumer concerns over the last 18 months, a shift formulators are answering with multi-ingredient personalization rather than single-actives, an evolution that will test how cleanly DSHEA structure/function claim rules scale to mass customization.

A side-by-side review of the CRN and NPA positions on mandatory product listing lays out where the two camps actually diverge: data scope, public-facing transparency, FDA enforcement leverage and the compliance burden on small and mid-sized brands. The piece is a useful primer for retailers and brand owners scoping the operational impact of either bill as they head into the second half of the legislative calendar.

MitoQ New Zealand signed an MOU with the National University of Singapore’s Healthy Longevity Translational Research Programme to run what the partners describe as the first supplement-efficacy study built around biological aging clocks. A 100-person controlled trial begins in July, pairing questionnaire-based assessments with epigenetic and LinAge clocks, an approach that could compress the timelines and costs of substantiating structure/function claims for the supplement industry.

A Nature Medicine analysis of 958 COSMOS participants found that two years of daily multivitamin–multimineral supplementation, but not cocoa extract, slowed multiple epigenetic aging clocks by about four months on average. Participants who were biologically older than their chronological age at baseline benefited most, a signal that should sharpen how brands describe nutritional adequacy versus disease-modification under DSHEA structure/function rules.

Wholesome Story co-founder and CEO Junghwa Detlefsen traces her company’s PCOS, fertility and postpartum portfolio to her own postpartum experience, and details how the brand calibrates structure/function language and clinical substantiation as women’s health VMS becomes one of the most regulator-watched corners of the category. The conversation is a useful operating-level read on translating DSHEA claim limits into a coherent product roadmap.

Coverage from the International Conference on the Science of Botanicals frames the central question facing botanical formulators: how do you separate genuine innovation from rebrands when FDA, plaintiffs’ attorneys and retailers are all paying closer attention to evidence? The agenda’s emphasis on identity, characterization and clinical substantiation maps directly to the NDI workstream FDA has flagged for 2026 deliverables.

With S. 3677 and H.R. 8370 both moving through committee and NPA Fly-In Day just behind us, members of Congress are actively measuring industry sentiment. Manufacturer, retailer and consumer voices over the next six weeks will shape whether DSHEA is modernized through a workable listing framework or layered with duplicative compliance costs.

CONTACT YOUR REPRESENTATIVE

Protecting consumer access to dietary supplements through education, advocacy and policy.

You are receiving this email because you subscribed to the DSHEA Weekly Digest. Unsubscribe · Update Preferences

Powered by PICXM